Last reviewed · How we verify
Risperidone immediate-release
Risperidone immediate-release, marketed by Johnson & Johnson Taiwan Ltd, is a well-established antipsychotic with a strong presence in the market. The key composition patent expires in 2028, providing a significant period of exclusivity and protection against generic competition. The primary risk is the eventual loss of patent protection, which could lead to increased competition from generics.
At a glance
| Generic name | Risperidone immediate-release |
|---|---|
| Also known as | Risperidone IR |
| Sponsor | Johnson & Johnson Taiwan Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder (PHASE3)
- Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 (PHASE3)
- A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (PHASE4)
- Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (PHASE1)
- A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug (PHASE4)
- A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia (PHASE1)
- As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone immediate-release CI brief — competitive landscape report
- Risperidone immediate-release updates RSS · CI watch RSS
- Johnson & Johnson Taiwan Ltd portfolio CI